Goldberg Law PC announces that it is investigating Seres Therapeutics, Inc. (“Seres” or the “Company”) (Nasdaq: MCRB) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Seres shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation concerns events around the Company’s announcement on July 29, 2016 that its Phase 2 clinical study for ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. When this news was released, shares of Seres dropped in value sharply. Two days before the announcement, however, the Company’s President, CEO and Chairman of the Board sold 20,000 shares of Seres at a much higher price.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005880/en/